All In Biotech

Drug Trial Radar · NCT01728155

European Low and Intermediate Risk Neuroblastoma Protocol

Last checked: Nov 20, 2026Latest source record: Sep 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 685 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

685

Actual

Start

Jan 1, 2011

Primary completion

Dec 31, 2022

Sponsor

Lead sponsor
Instituto de Investigacion Sanitaria La FeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 90 days, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The European study, LINES 2009 (Low and Intermediate Risk Neuroblastoma European Study), groups together in a single protocol the treatment of all patients with "non high risk" neuroblastoma (NB), with stratification into two groups: low risk and intermediate risk. These two separate cohorts are included in one single protocol to enable patient data from these two groups to be entered into a common database, as the current prognostic classifications determining treatment may evolve further with subsequent more detailed molecular analysis of the tumours. 1\. LOW RISK STUDY The Low Risk Study is proposed in order to: * minimise the amount of treatment (chemotherapy and surgery) for all appropriate low risk patients, who in previous studies have been shown to have an excellent long-term outcome (as in the SIOPEN 99.1-2 infant neuroblastoma studies where the overall survival was greater than 97%(H. Rubie, JCO). * improve the EFS and maintain the OS (overall survival) in L2 and Ms patients with a SCA(Segmental Cromosomal Aberration) genomic profile tumour (presence of any segmental chromosomal change (SCA)) by electively treating these patients with chemotherapy despite the absence of symptoms. 2\) INTERMEDIATE RISK STUDY The Intermediate Risk Study is proposed in order to: * reduce the amount of chemotherapy for differentiating histology INRG (International Neuroblastoma Risk Group) stage L2 NB and ganglioneuroblastoma nodular patients who in previous SIOPEN study have been shown to have an excellent long-term outcome; * increase the amount of treatment (radiotherapy and 13-cis-RA (13-cis-Retinoic Acid) for poorly differentiated or undifferentiated histology INRG stage L2 NB or ganglioneuroblastoma nodular patients in order to improve the EFS registered in the previous SIOPEN study; * improve the EFS (Event Free Survival) of MYCN (V-Myc myelocytomatosis viral related oncogene, NB derived ,avian )amplified INSS (International NB Staging System) stage 1 NB patients with the introduction of adjuvant treatment; * maintain the very good results obtained in previous SIOPEN study for INRG stage M infants with a moderate treatment. NEONATAL SUPRARENAL MASSES The incidence of suprarenal tumours/masses has increased in the last decade due to the expanded use of prenatal ultrasonography in routine obstetric care and in the neonatal and early infancy care. The differential diagnosis of these masses ranges from benign (adrenal haemorrhage) to malignant processes (neuroblastoma, adrenal carcinoma). Knowledge on perinatal suprarenal masses, although based on a relatively large literature, is scattered amongst studies on very few cases with no methodical approach and often short follow up. Therefore, the optimal management of these masses has not been clearly defined. Neuroblastoma at this age is an intriguing entity with a very good prognosis in most cases. The SIOPEN Group, based on their results in the first multicenter European Trial for infants with neuroblastoma (INES) and the world-wide experience provided in the literature, is launching this European surveillance study (Multi-centre, non-blinded, one armed prospective trial) for these masses. Treatment: Observation

Conditions

  • LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES

Interventions

  • chemotherapyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary aim for Low Risk NeuroblastomaTime frame: 2 years
  2. Primary aim for Intermediate Risk NeuroblastomaTime frame: 2 years
  3. Primary Aim for Neonatal Suprarenal MassesTime frame: 3 year

Locations

98 sites in 10 countries. Site status is shown where the registry gives one.

  • Monash Children's Hospital

    Clayton, Australia

  • Perth Children's Hospital

    Nedlands, Australia

  • Sydney Children's Hospital

    Sydney, Australia

  • PHO Med Uni Graz

    Graz, Austria

  • Department Kinder- und Jugendheilkunde

    Innsbruck, Austria

  • Landes-Frauen- und Kinderklinik Linz

    Linz, Austria

  • St. Anna Kinderspital

    Vienna, Austria

  • Univ Klinik für Kinder- und Jugendheilkunde

    Vienna, Austria

  • Hôpital Universitaire d'Anvers (UZA- Universitair Ziekenhuis Antwerpen)

    Antwerp, Belgium

  • Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)

    Brussels, Belgium

  • UCL Clíniques Universitaires Saint - Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

  • CHC- Clinique de l'Espérance à Liège

    Liège, Belgium

  • CHR de la Citadelle

    Liège, Belgium

  • Aarhus University Hospital

    Aarhus, Denmark

  • National State Hospital (Department of Pediatrics)

    Copenhagen, Denmark

  • University Hospital of Odense (H.C. Andersen Children´s Hospital)

    Odense, Denmark

  • Soroka Medical Center

    Beersheba, Israel

  • Rambam Health Care Campus

    Haifa, Israel

  • Schneider Children's Medical Center

    Petah Tikva, Israel

  • Ichilov Hospital Sourasky Medical Center

    Tel Aviv, Israel

  • Ospedale Pediatrico G. Salesi di Ancona (Centro Regionale Oncoematologia Pediatrica)

    Ancona, Italy

  • Azienda Ospedaliera - Universitaria Ospedale Policlinico Consorziale

    Bari, Italy

  • Azienda Ospedaliera Ospedali Riuniti di Bergamo

    Bergamo, Italy

  • Azienda Ospedaliero- Universitaria di Bologna- Policlinico S. Orsola - Malpighi

    Bologna, Italy

  • Azienda Ospedaliera Spedali Civili di Brescia

    Brescia, Italy

  • Ospedale Microcitemico

    Cagliari, Italy

  • Oncology Policlinico- Department of Hematology

    Catania, Italy

  • Azienda Ospedaliero-Universitaria di Ferrara- Oncoematologia Pediatrica

    Ferrara, Italy

  • Azienda Ospedaliero-Universitaria Ospedale Pediatrico Meyer

    Florence, Italy

  • Oncology Gaslini Children's Hospital of Genova- Department of Hematology

    Genova, Italy

  • Istituto Nazionale dei Tumori di Milano- Onco-ematologia Pediatrica

    Milan, Italy

  • Azienda Ospedaliero-Universitaria Policlinico di Modena- Onco-ematologia Pediatrica

    Modena, Italy

  • Azienda Ospedaliera Pediatrica Santobono Pausilipon

    Naples, Italy

  • Sec. Università degli studi di Napoli - Policlinico

    Naples, Italy

  • Azienda Ospedaliera-Universitaria di Padova- Clínica di Onco-ematologia Pediatrica

    Padova, Italy

  • Ospedale dei Bambini G. Di Cristina

    Palermo, Italy

  • Azienda Ospedaliero - Universitaria di Parma- Oncoematologia Pediatrica

    Parma, Italy

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.